… inhibition of human breast cancer cells and prostatic cancer cells. In this study, we demonstrated
that PPAR- , but not PPAR- , was expressed in human lung cancer … human lung cancer …

… Collectively, our findings identify a spectrum of mechanisms sufficient to confer resistance
to ALK inhibitors in NSCLC and suggest a role for P2Y receptors and PKC signaling in …

… receptor (EGFR) inhibitors such as gefitinib show antitumor activity in a subset of non–small
cell lung cancer … expressing ErbB-3 and that EGFR inhibitors do not inhibit PI3-K signaling in …

… Globally, lung cancer is the leading cause of cancer deaths … 70% to 80% of lung cancer cases
2 and is generally diagnosed … advanced non-small cell lung cancer (NSCLC) remains poor…

… of non–small-cell lung cancer (NSCLC). The discovery that mutations in the TK domain are
associated with dramatic and sustained responses to EGFR TK inhibitors (TKIs) has allowed …

… We identified CRKL amplification in an EGFR inhibitor–treated lung adenocarcinoma that …
resistance to epidermal growth factor receptor inhibitor treatment and suggest that therapeutic …

… Epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and
erlotinib, show excellent clinical efficacy for patients with non-small cell lung cancer (NSCLC) with …

… cell lung cancer (NSCLC) is the leading cause of cancer … growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs). … -line chemotherapy for pulmonary lung adenocarcinoma among …

… inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment
options for non-small cell lung cancer … , treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls). …

… for the lung carcinogenesis and … receptors (erbB1 (EGFR), erbB2 (HER2), erbB3 and
erbB4) seems to play an important role for the lung cancer development, and several inhibitors …